Company Analysis Gilead Sciences
1. Summary
Advantages
- Dividends (3.98%) are higher than the sector average (0.5491%).
- The stock's return over the last year (0.0612%) is higher than the sector average (-29.77%).
- Current debt level 40.22% is below 100% and has decreased over 5 years from 42.9%.
- The company's current efficiency (ROE=24.9%) is higher than the sector average (ROE=9.61%)
Disadvantages
- Price (81.7 $) is higher than fair price (49.8 $)
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
18 november 17:19 COVID-19 vaccine start-up files for IPO
18 november 16:26 Inside the race for a COVID-19 treatment pill
Other news β¨
2.3. Market efficiency
| Gilead Sciences | Healthcare | Index | |
|---|---|---|---|
| 7 days | -10.9% | -16.4% | -1.7% |
| 90 days | 9.9% | -46.1% | 7.1% |
| 1 year | 0.1% | -29.8% | 32.3% |
GILD vs Sector: Gilead Sciences has outperformed the "Healthcare" sector by 29.83% over the past year.
GILD vs Market: Gilead Sciences has significantly underperformed the market by -32.2% over the past year.
Stable price: GILD is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: GILD with weekly volatility of 0.0012% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Above fair price: The current price (81.7 $) is higher than the fair price (49.8 $).
Price is higher than fair: The current price (81.7 $) is 39% higher than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (17.69) is lower than that of the sector as a whole (48.77).
P/E vs Market: The company's P/E (17.69) is lower than that of the market as a whole (48.05).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (4.41) is lower than that of the sector as a whole (4.82).
P/BV vs Market: The company's P/BV (4.41) is higher than that of the market as a whole (3.1).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (3.7) is lower than that of the sector as a whole (33.76).
P/S vs Market: The company's P/S indicator (3.7) is lower than that of the market as a whole (10.14).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (15.66) is higher than that of the sector as a whole (-22.12).
EV/Ebitda vs Market: The company's EV/Ebitda (15.66) is lower than that of the market as a whole (19.1).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Rising and has grown by 1.02% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (1.02%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-9.16%).
5.4. ROE
ROE vs Sector: The company's ROE (24.9%) is higher than that of the sector as a whole (9.61%).
ROE vs Market: The company's ROE (24.9%) is higher than that of the market as a whole (10.87%).
5.5. ROA
ROA vs Sector: The company's ROA (9.12%) is higher than that of the sector as a whole (0.3359%).
ROA vs Market: The company's ROA (9.12%) is higher than that of the market as a whole (6.5%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (11.06%) is higher than that of the sector as a whole (7.63%).
ROIC vs Market: The company's ROIC (11.06%) is higher than that of the market as a whole (10.79%).
7. Dividends
7.1. Dividend yield vs Market
High yield: The dividend yield of the company 3.98% is higher than the average for the sector '0.5491%.
7.2. Stability and increase in payments
Dividend stability: The company's dividend yield 3.98% has been steadily paid over the past 7 years, DSI=0.93.
Weak dividend growth: The company's dividend yield 3.98% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (67.24%) are at a comfortable level.
8. Insider trades
8.1. Insider trading
Insider Selling More insider purchases by 293.84% over the last 3 months.
8.2. Latest transactions
| Transaction date | Insider | Type | Price | Volume | Quantity |
|---|---|---|---|---|---|
| 12.09.2024 | Parsey Merdad Chief Medical Officer |
Sale | 84.5 | 1 795 290 | 21 246 |
| 12.09.2024 | Parsey Merdad Chief Medical Officer |
Purchase | 57.92 | 1 448 000 | 25 000 |
| 12.09.2024 | Mercier Johanna Chief Commercial Officer |
Sale | 83.78 | 2 459 530 | 29 357 |
| 01.07.2024 | Parsey Merdad Chief Medical Officer |
Sale | 68.63 | 137 260 | 2 000 |
| 29.02.2024 | Parsey Merdad Chief Medical Officer |
Sale | 72.74 | 598 650 | 8 230 |
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
